Updated Data on Reata Pharmaceuticals, Inc.'s Two Clinical Candidates Presented at 2008 Annual Meeting of the American Association for Cancer Research

IRVING, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. announced today the presentation of significant new preclinical data on its two clinical-stage compounds, berubicin hydrochloride (an anthracycline derivative formerly known as RTA 744) and RTA 402 (the lead agent in Reata’s portfolio of Antioxidant Inflammation Modulators, or AIMs, also known as CDDO-Me).